A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C - Concepedia

Concepedia

Publication | Closed Access

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

158

Citations

23

References

2012

Year

Eric Lawitz, Daniel Gruener, John M. Hill, Thomas Marbury, Lisa Moorehead, Anita Mathias, Guofeng Cheng, John O. Link, Kelly A. Wong, Hongmei Mo,

Journal of Hepatology

HepatologyHepatitis CMedicineViral HepatitisAntiviral TherapyHepatitisPharmacotherapyLiver DiseasePharmacologyPhase 1Genotype 1

References

	Year	Citations

Page 1

Page 1